Search

Author/Creator Bonnefoi, H

1. 150O_PRPertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG). (13th May 2019)

Authors:
Huober, J; Ribi, K; Weder, P; Li, Q; Vanlemmens, L; Gerard, M-A; Lemonnier, J; Thürlimann, B; Boven, E; Bonnefoi, H
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 288PDPERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207). (23rd October 2018)

Authors:
Huober, J; Weder, P; Veyret, C; Thürlimann, B; Xyrafas, A; Vanlemmens, L; Guiu, S; Brain, E; Grenier, J; Dalenc, F; Levy, C; Savoye, A M; Müller, A; Membrez-Antonioli, V; Gerard, M A; Lemonnier, J; Hawle, H; Boven, E; Bonnefoi, H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306). (23rd October 2018)

Authors:
Bonnefoi, H; Levy, C; MacGrogan, G; Grellety, T; Asselain, B; Pulido, M; Everhard, S; Lemonnier, J; Gonçalves, A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019)

Authors:
Piprot, C; Cals, L; Chaigneau, L; Demarchi, F; N'Guyen, T; Stein, U; Villanueva, C; Bréau, JL; Chouahnia, AK; Saintigny, P; Boué, F; deSaint-Hilaire, P; Guimont, I; Grossat, N; Valenza, B; Lévy, E; Médioni, J; Delbaldo, C; Grenier, J; Pouessel, D
Journal:
Lancet
Issue:
Volume 393:Issue 10191(2019)
Page Start:
2591
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019)

Authors:
Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, Pierre; Serin, Daniel; Jacquin, Jean-Philippe; Jouannaud, Christelle; Rios, Maria; Abadie-Lacourtoisie, Sophie; Venat-Bouvet, Laurence; Cany, Laurent; Catal...
Journal:
Lancet
Issue:
Volume 393:Issue 10191(2019)
Page Start:
2591
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 92PDetection of PIK3CA mutation by circulating DNA during chemotherapy: A tool to identify hard-to-treat metastatic breast cancers. (7th November 2019)

Authors:
Mosele, F; Lusque, A; Tran Dien, A; Droin, N; Le Tourneau, C; Sablin, M P; Lacroix, L; Miran, I; Jovelet, C; Bieche, I; Soria, J-C; Bertucci, F; Bonnefoi, H; Campone, M; Dalenc, F; Bachelot, T; Jacquet, A; Jimenez, M; André, F
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 7
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. (25th October 2017)

Authors:
Criscitiello, C; Bayar, M A; Curigliano, G; Symmans, F W; Desmedt, C; Bonnefoi, H; Sinn, B; Pruneri, G; Vicier, C; Pierga, J Y; Denkert, C; Loibl, S; Sotiriou, C; Michiels, S; André, F
Journal:
Annals of oncology
Issue:
Volume 29:Number 1(2018)
Page Start:
162
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (3rd May 2018)

Authors:
Curigliano, G; Burstein, H J; Winer, E P; Gnant, M; Dubsky, P; Loibl, S; Colleoni, M; Regan, M M; Piccart-Gebhart, M; Senn, H -J; Thürlimann, B; André, F; Baselga, J; Bergh, J; Bonnefoi, H; Brucker, S Y; Cardoso, F; Carey, L; Ciruelos, E; Cuzick, J
Journal:
Annals of oncology
Issue:
Volume 29:Number 10(2018)
Page Start:
2153
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (25th September 2017)

Authors:
Dubsky, P; Curigliano, G; Burstein, H J; Winer, E P; Gnant, M; Loibl, S; Colleoni, M; Regan, M M; Piccart-Gebhart, M; Senn, H -J; Thürlimann, B; André, F; Baselga, J; Bergh, J; Bonnefoi, H; Brucker, S Y; Cardoso, F; Carey, L; Ciruelos, E; Cuzick, J
Journal:
Annals of oncology
Issue:
Volume 29:Number 1(2018)
Page Start:
281
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗